

Index

Page numbers in “*Italics*” refer to figures; page numbers in “**bold**” refer to tables.

- 2SLGBTQIA+ populations, 122, 130
- Aboriginal peoples, 129
- acetazolamide, 144
- active epilepsy, 216
 - hyperprolactinemia and, 159
 - statistics on, 1
- acute insomnia, role of
 - pharmacotherapy in treating, 54
- acute seizures
 - effects of, 160
 - management of, 224
- acute symptomatic seizures, 101
- adolescents
 - bullying and violence, 126
 - caring for young, 130
 - compliance with taking medications, 124
 - development of, 123
 - inheritance and genetics, 7–8
 - lifestyle changes due to epilepsy, 123
 - quality of life for, 125
 - seizure triggers and, 124
 - self-image and, 124–5
 - sex differences in epilepsies, 8
 - sexual awakening and, 124–5
 - stigma of epilepsy for, 122
 - transitional care for, 126–8
- aging and epilepsy, 316
- Aicardi syndrome, 114–15
- airway management, 257–8
- allopregnanolone, 66, 70–1
 - anticonvulsant effects of, 70
 - as a mediator in stress response, 26
 - effect of, 29
 - progesterone and, 137
- alternative medicine, 40
- amenorrhea, 86
 - contraceptions and, 173
 - hyperprolactinemia and, 159
 - hypothalamic, 10, 159
- intramuscular injection and, 172
- premature menopause and, 159
- progesterone therapies and, 143
- temporal lobe epilepsy and, 158
- American Academy of Neurology (AAN), 11, 209, 210, 284
 - 2009 Practice Parameter, 181
- American Association of Clinical Endocrinology and American College of Endocrinology Clinical Practice Guidelines, 314
- American College of Obstetricians and Gynecologists, 242
- American Epilepsy Society (AES), 11, 210
- AMPA receptor upregulation, 72
- analgesics, opioid, 262
- androgenization, 41
- anesthesia/anesthetics
 - anesthetic induction agents, 260–1
 - antiseizure medications (ASMs) and, 258–9
 - local, 259–60
 - neuromuscular blocking agents, 261–2
 - obstetric, 257
 - opioid analgesics, 262
 - volatile anesthetics, 261
- aneuploidy screening, 236
- anhedonia, 26, 87
- antenatal management, of epilepsy, 236
- antepartum hemorrhage, 220, 235
- anterior temporal lobectomy (ATL), 161
- anticholinesterases, 262
- anticonvulsants, 41, 259, 262
 - progesterone as, 70–1
- antidiuretic hormone, 93–4
- AntiEpileptic drug Monitoring in PREgnancy (EMPIRE) study, 223
- antiepileptic drugs, 174
 - effects of on reproductive hormones, 174–6
 - effects on cognition, 180
 - risk of use in pregnancy, 178–82
 - risks of, 183
- antiseizure medications (ASMs), 221
 - adverse effects on behavioral outcome, 208
 - antidiuretic hormone-related hyponatremia and, 93–4
 - benefits of breastfeeding for infants exposed to, 281
 - bidirectional interactions of hormonal contraceptives and, 174–6
 - breastfeeding and, 183, 290
 - breastfeeding safety and, 284–7
 - by psychiatric effects, 34
 - childbearing-age women and, 279–80
 - congenital malformations and, 180
 - dosage during pregnancy, 266
 - effect of exposure to breastfed infants, 284
 - effect of pharmacokinetics on, 217
 - effect of on bone health/metabolism, 89, **90**, 311–13
 - effect of on cognitive development, 206–7
 - effect on sleep, 50
 - endocrine-related side effects, 84

- epidemiological data on use of, 194–8
- fertility/infertility and, 149, 163
- fetal malformations risks from using, 12–15, 181, 198–204
- hazardous ASMs and breastfeeding, 287–8
- hepatic enzyme inducing, 85–6
- hormonal control of glucose metabolism and weight, 90–2
- hormone interaction and, 138
- management of, 271
- monotherapy, 9
- neuropsychiatric effects of, 34
- new generation of, 218, 266–8
- non-enzyme-inducing, 86–8
- older generation of, 268–9
- psychiatric and behavioral adverse effects, 35
- recommendations during lactation, 284–7
- reproductive and endocrine effects of, 85
- reproductive disturbances and, 161–3
- risks from using, 204
- sedating, 50
- sexual dysfunction and, 9, 219
- sleep disorders and, 46
- thyroid hormones and, 92–3
- treatment in pregnancy, 219
- with limited data, 288–9
- withdraw of sedating, 50
- withdrawal from using, 222–3
- WWE and taking, 279–80
- anxiety/anxiety disorders, 6, 29, 52, 273
- antiseizure medications (ASMs) and, 88
- during pregnancy, 215
- gabapentin and pregabalin as treatment of, 34
- maternal mental illness and, 235
- mothers with epilepsy and, 281
- PNES patients and, 33
- premenstrual syndrome and, 27–8
- risk of developing epilepsy and, 3, 25
- seizures and, 221
- sleep loss and, 50, 54
- treatment of, 41
- assessment, long-term follow-up, 300
- Atkins diet, modified, 289
- atracurium, 261
- attention deficit hyperactivity disorder (ADHD), 31, 122, 130
- NEAD study and, 208
- Australian Pregnancy Register (APR), 13, 194, 200, 205, 222
- for WWE and Allied Disorders, 15
- major congenital malformation rates and, 204, 209
- study of ASM-treated pregnancies, 15
- autism spectrum disorder (ASD), 32, 113, 122–3, 130, 180, 208, 236
- maternal use of VPA and risk of, 15
- reduced rates of, 209
- risk of, 301
- West and Lennox–Gastaut syndromes and, 32
- Axial FLAIR sequences, 246, 250
- barbiturates, 50, 55, 275
- sedating effect of, 225
- behavioral problems, 31–2, 110, 208, 301
- of youth, 127
- benzodiazepines, 41, 55, 85, 89, 144, 204, 225, 263, 275, 297, 307
- as an anesthetic induction agent, 260
- catamenial epilepsy and, 144
- sedating effect of, 50, 225
- treatment for insomnia, 54
- treatment for restless leg syndrome, 55
- treatment for status epilepticus (SE), 74
- treatment of psychosis and, 41
- biological antagonism
- neuropsychiatric disorders, 293
- psychiatric disorders and, 39
- bipolar disorders, 26, 28–9, 31, 201, 293
- family history of, 37
- treatment of, 34, 41
- bone health, 17–18
- antiseizure medications (ASMs) effect on, 89
- fractures and, 311–13
- in perimenopausal women, 309–10
- mechanisms of osteoporosis, 310–11
- recommendations for, 91
- screening of at risk individuals, 313–14
- treatment, 314
- bone metabolism, 316
- abnormal, 89
- ASM monotherapy and, 89
- effects of antiseizure medications on, 90
- bone mineral density (BMD), 310
- bone physiology, 310, *See also* bone health
- brain maturation, 300
- brain tumors, 250–1
- other primary, 251
- breakthrough seizures, 224, 237, 266, 269, 272, 281
- dose optimization for, 268
- during pregnancy, 224
- postpartum period and, 265, 274
- breastfeeding. *See* lactation (breastfeeding)
- benefits for infants of WWE taking ASMs, 281
- benefits of, 280–1
- epilepsy and during the postpartum period, 274–6
- hazardous antiseizure medications (ASMs) and, 287–8
- level of infant's drug exposure via breast milk, 282
- neurodevelopmental benefits, 183
- safe antiseizure medications (ASMs) during, 284–7
- sleep recommendations for WWE and, 289
- women with epilepsy and, 281
- breathing, sleep-disordered, 52, 54–5, 57

- bright light therapy, 40
brivaracetam, 218, 220, 288
bromide, 114
- calcium supplementation, 90
Canadian health survey, 4
CANMAT/ISBD guidelines, 41
carbamazepine (CBZ), 85, 93, 218, 268, 287
 effect on neurocognitive development, 207
 malformations with the use of monotherapy, 198–200
 psychotropic medications, 35
 treatment, 314
 with St. John's wort, 40
catamenial epilepsy, 8, 65–6, 134, 146
 animal studies and, 66–70
 definition and prevalence of, 138–9
 definition of catamenial, 134
 diagnosis, 139
 hormonal strategies for managing, 142–4
 management strategies for, 140–1
 menopause and, 145
 nonhormonal strategies for, 144–5
 pathophysiology of, 135
 pregnancy and, 145
 progesterone therapies for, 142–4
catheter angiography, 246, 249, 252
CDKL5 deficiency disorder (CDD), 74, 107, 109–10
Centers for Disease Control and Prevention (CDC), 11, 202
 breastfeeding report card, 281
 Medical Eligibility Criteria for Contraception, 175
 report card, 281
cerebral lateralization, 300
cerebral venous thrombosis, 228
 pregnancy and, 247–9
 risk factors for, 247
Child Behavior Checklist, 208
childbearing age, 65, 177, 186, 201, 221
 counseling and, 12
 counseling and evaluating women with epilepsy, 164
 folic acid supplementation and women of, 181, 210, 222
 levetiracetam (LEV) for women of, 202
 prepregnancy counseling and, 11
 risks of topiramate and phenobarbital for, 180
 valproate and, 116
 with drug-resistant focal epilepsy, 161
 women of, 194
childhood
 compliance with taking medications, 124
 psychiatric comorbidities in, 122–3
childhood absence epilepsy (CAE), 116
 sex differences and, 8
children. *See also* adolescents
 inheritance and genetics, 7–8
 maladaptive behavior and exposure to ASMs, 208
 sex differences in epilepsies, 8
 sleep problems and, 7
 with ADHD and development of epilepsy, 31
chronic epilepsy, 30, 316
 effects of, 160
circadian influences, 46, *See also* sleep
 on epilepsy, 47–8
 on physiology and behavior, 51
 problems and, 109
Cleveland Clinic, 7
clobazam, 114, 144–5, 218, 285, 288
clonazepam, 288
cognitive behavioral therapy (CBT), 37, 53
 treatment of perimenopausal insomnia, 59
cognitive development, 180, 209, 301
 effect of antiseizure medications (ASMs) on, 206–7, 208
 effect of levetiracetam (LEV) on, 207
 folic acid for, 181
 tonic-clonic seizures in pregnancy and, 182
cognitive dysfunction, 112
combination therapy, 285
comorbid neurodevelopmental disorders, 31, *See also* neurodevelopmental disorders
complementary and alternative medicine, 40
computed tomography (CT), 241–2
 and radiation exposure. *See also* fetus; unborn child
 radiation exposure and, 242
congenital malformations, 193–4, 301, *See also* teratogenesis
 antiepileptic drugs and major, 178–82
 effects of antiseizure medications dosage on, 180
 major, 144, 220, 228, 233, 279
continuous positive airway pressure (CPAP), 52, 55
contraception
 combination methods, 173
 contraceptive implant, 172
 dual method, 173
 hormonal, 11
 hormonal contraceptives and antiseizure medications, 174–6
 implant, 172
 intramuscular injection, 172
 intrauterine device (IUD), 170–2
 long-acting reversible, 170–3
 methods of, 170
 oral contraceptives, 172–3
 preconception planning and, 185–6
 selecting for women with epilepsy (WWE), 169–73
 use in women with epilepsy, 169–70
contraceptives. *See also* contraception
 as a therapeutic tool, 176–7

- available in the United States, 171
 hormonal, 52
 management of for women with epilepsy (WWE), 11
 cortex syndrome, 110
 counseling, 18, 314
 about postpartum safety, 269
 and infertility, 163
 preconception, 11–12, 177, 185–6, 221, 228, 236
 cross-sex steroids (estradiol), 130
 CT venogram (CTV), 247
 CYP2C19, 218
 Cytochrome P450 (CYP450)-enzyme system, 17, 283
 ASMs and, 209, 235, 310–11
 hepatic, 85, 138, 174
 St. John's wort and, 40
 cytochrome p450 isoenzymes, 310
- Danish health registers, 200
 Danish National Prescription Registry, 207
 Danish Twin Registry, 8
 daytime sleepiness, 54, 56, 57,
 See also sleep; sleep disorders
 excessive, 6, 48, 52
 hormone replacement and, 59
 pregnancy and, 56
 delivery
 breastfeeding after, 285
 cesarean, 57, 247
 complications related to epilepsy, 15–16
 delayed eclampsia after, 245
 medication and, 228
 risk for preterm, 294
 risk of seizures during, 224, 237
- Denmark
 age and gender-specific incidence of epilepsy in, 2
 antiseizure medications (ASMs) use and fracture risk, 312
 maternal death and epilepsy in, 235
 phenobarbital (PB) exposure during early development, 207
 statistics on childhood autism in, 301
 study on utero exposure to newer-generation ASM, 13
 Department of Health Clinical Standards Advisory Group of the United Kingdom, 269
 depot medroxyprogesterone acetate (DMPA), 172
 depression, 28–9, 52
 anxiety and, 88, 235, 273
 neurovegetative symptoms of, 27
 perinatal, 27, 40
 peripartum, 273
 risk of developing, 25
 desvenlafaxine, 40
 direct biological effects, infertility and, 156
 driving
 adolescents with epilepsy and, 124
 limitations to, 316
 safety during the postpartum period, 276
 sleep disruption and safe, 61
 drug exposure, via breastmilk, 282
 drugs
 indices of infant's exposure to, 282–3
 infant's metabolism and clearance and, 283–4
 physiochemical properties of, 282
 Dutch outpatients, prevalence of sleep disturbances in, 6
 early pregnancy
 bleeding in, 16
 counseling and, 236
 eclampsia, 241, 244–7
 seizures secondary to, 225–5
 education, impact of epilepsy on, 128
 electrical status epilepticus during sleep (ESES), 108
 electroconvulsive therapy (ECT), 39
 electromyography, 47
 electrooculography, 47
 enzyme-inducing antiseizure medications (ASMs), 85, 89, 310–11
 replacing, 90
 enzyme isomers, 283
 epilepsies. *See* epilepsy
 epilepsy
 active, 159, 216
 antenatal management of, 236
 bimodal distribution of, 2
 catamenial, 8
 chronic, 30, 316
 comorbidities and, 3–4
 diopathic generalized, 178
 education status of persons with, 128
 effects of chronic, 160
 effects of pregnancy on, 231–3
 fertility rates in women with, 150, 151
 fetal and neonatal outcomes associated with, 233–4
 focal, 29, 31
 generalized, 7, 216
 genetic forms of, 117
 genetic generalized, 116, 139
 heritability of, 178
 identifying psychiatric comorbidities, 122
 idiopathic generalized, 124
 incidence of, 1–2, 101
 Indigenous girls and adolescent women, 129–30
 juvenile myoclonic, 115–16, 124
 lesional, 101
 lifetime risk of, 2
 marriage rate among persons with, 128–9
 maternal, 169, 194, 293, 301
 maternal outcomes and, 234, 235–6
 median lifetime prevalence of, 1
 new onset epilepsy during pregnancy, 293
 non-catamenial, 216
 overall incidence rate of, 2
 PCDH19, 113–14
 pharmacoresistant, 102–6
 potential causes of sex differences, 2–3

- epilepsy (cont.)
 preconception management
 of, 221–2
 pregnancy and delivery
 complications related
 to, 15–16
 prevalence of, 1–3
 psychiatric disorders
 and, 4–6
 psychiatric phenomena
 linkage and, 25
 psychosocial and cultural
 considerations when
 caring for patients,
 128–30
 role of inheritance and
 genetics in, 7–8
 seizures secondary to, 224–5
 self-limited focal, 47
 sex difference in
 prevalence, 1
 sex differences in children
 and adolescents, 8
 sleep disorders and, 46, 61
 sleep-related, 49
 statistics on, 1
 temporal lobe, 29
 type and etiology of epilepsy,
 156–8
 X-linked, 113
 Epilepsy Birth Control Registry
 (EBCR), 10, 169
 Epilepsy Foundation
 My Seizure Diary, 271
 epilepsy surgery, 28, 161
 effect on menstrual
 disturbances, 156
 epilepsy syndromes, 32, 47,
 180, 289
 limited to females, 101
 recognizing and diagnosing,
 101–7
 sex differences in, 8
 epileptic lesion, laterality of
 the, 160–1
 epileptogenesis, 73
 eslicarbazepine, 218
 estrogen/estrogens, 73
 estradiol, 72
 estrogen/estrogens, 50–1, 64–5,
 77, 135
 effect of increase in, 163
 neuronal effects of, 72–3
 neuroprotective effects of, 314
 treatment of bone loss
 with, 90
 water-soluble, 135
 estrous cycle, 66, 72, 74
 etomidate, 261
 EURAP study, 12, 15, 182,
 224, 232
 antiseizure medications
 (ASMs) risk, 200
 comparison of different
 ASM types, 233
 levetiracetam use, 202
 limitation of, 195
 major congenital
 malformations, 205
 pregnancy registries, 194–5,
 198, 200, 201, 224, 228
 rate of major congenital
 malformations and, 180
 valproic acid withdrawal
 group, 222
 zonisamide use, 204
 EUROCAT database, 201
 European International
 Antiepileptic Drug and
 Pregnancy Registry
 (EURAP). *See* EURAP
 study
 excessive daytime sleepiness.
 See daytime sleepiness
 exercise monotherapy, 40
 fast spin echo T2- weighted
 (FSET2), 246
 felbamate, 92, 288
 female puberty, 130
 fertility
 impact of social factors and
 stigma on, 154–5
 normalized rate of, 150
 rates in women with epilepsy
 (WWE), 10–11, 150, 154
 women with epilepsy
 (WWE) and, 9–11
 fetal anatomical
 assessment, 236
 fetal and neonatal outcomes,
 233–4
 fetal malformations
 antiseizure medications
 (ASMs) and, 12–15, 181
 family history of, 168
 risks of, 12
 valproic acid and, 222
 fetus
 computed tomography (CT)
 and radiation
 exposure, 242
 effect of iodinated contrast
 medium on, 243
 gadolinium-based contrast
 medium and safety of
 the, 244
 magnetic resonance imaging
 (MRI) and safety of the,
 243–4
 safety of the, 242–4
 finasteride, 67
 Finnish Drug Prescription
 Database, 194
 fluid-attenuated inversion
 recovery (FLAIR), 246
 focal epilepsies, 29, 31
 childbearing age and, 161
 folic acid, 222
 role of, 208–10
 supplementation, 11–12,
 181–2, 209–10, 222,
 236, 301
 supplementation and
 spontaneous abortion
 and, 12
 use of preconceptual, 11
 follicular stimulating hormone
 (FSH), 64, 135
 fractures, 17–18, 89, 309
 antiseizure medications
 (ASMs) and increased
 risk for, 313
 bone health and, 311–13
 generalized tonic-clonic
 seizures and, 313
 risk of, 172
 FRAX®, 313
 free carbamazepine, 218
 GABA_A receptors, 70
 GABAergic inhibition, 71,
 73
 GABAergic transmission, 27
 gabapentin (GBP), 13, 34, 85,
 87, 267, 286, 294, 309
 risks of fractures and use of,
 89, 315
 treatment for restless leg
 syndrome, 55
 gadolinium-based contrast
 medium, 244, 247,
 252, 253
 gamma-amino-butyric acid
 (GABA)
 conductance, 307
 ganaxolone, 74–7, 114
 clinical trials of, 75–6

- gastroesophageal reflux disease (GERD), 56
- General Practice Research Database (GPRD), 312
- generalized anxiety disorder (GAD), 29
- generalized epilepsies, 7
- genetic generalized epilepsies (GGE), 107, 116, 139
- sex differences in incidences of, 101
- genetic testing, 107, 234
- children and
- adolescents, 7–8
- gestational hypertension, 16
- girls and young adolescents
- caring for, 130
- gliomas, low grade, 251
- Global health Observatory data, 126
- glomerular filtration rate (GFR), 217
- glucose metabolism and weight, 90–2
- glucuronidation, 163
- gonadotropin releasing hormone (GnRH), 41, 64, 135, 156
- gradient echo (GRE) sequences, 246
- growth and development, 300
- GSK-LTG registry, 194
- halogenated hydrocarbons, 261
- hazardous antiseizure medications (ASMs), 287–8
- HELLP syndrome (Hemolysis, Elevated Liver Enzymes, Low Platelets), 247
- hepatic CYP450, 89
- hepatic cytochrome P450, 85
- hepatic enzyme inducing antiseizure medications (ASMs), 85–6
- heterotopia, 111
- neuronal, 110
 - periventricular nodular, 112–13
 - subcortical band, 107, 110–12, 111
- higher apnea–hypopnea index (AHI), 51
- home safety strategies, 275
- hormonal changes, 73, 92, 162, 163, 215
- adjusting to changes after childbirth, 265
- adolescence and, 65
- during pregnancy, 145
- in menopause, 306–7
- lamotrigine and, 266
- occarbazepine and, 267
- sensitivity to, 146
- sleep deprivation and, 57
- hormonal contraceptives, 52
- antiseizure medications (ASMs) and bidirectional interactions of, 174–6
- effects of on antiseizure medications (ASMs), 175–6
- recommendations for use of, 175
- hormonal strategies, management of catamenial epilepsy with, 142–4
- hormone replacement therapy (HRT), 51, 59, 65
- effect of epilepsy treatment on, 17
- epilepsy and, 308–9
- synthetic, 308
- hormones
- antiseizure medications interactions with, 138
 - female reproductive, 77
 - neuroactive sex, 135
 - sex, 156
 - sexual function and, 155
 - status epilepticus (SE) and, 73–4
- human chorionic gonadotropin β subunit (β -HCG), 67
- hyperactive hypothalamic-pituitary-adrenal (HPA) axis, 26
- hypercarbia, 259
- hyperemesis gravidarum, 215
- hyperprolactinemia, 159
- hypersomnia, 37, 51
- menstrual-related, 52
- hypertensive disorders of pregnancy, 235
- hypoestrogenism, in menopause, 17
- hypogonadotropic hypogonadism, 10
- hypomania, 28
- hyponatremia, 93–4
- hyposexuality, 156
- breakdown of, 85
- hypothalamic amenorrhea, 159, *See also* menstrual disorders
- hypothalamic hypogonadism, 158–9
- hypothalamic-pituitary-gonadal axis, 156
- hypothalamic-pituitary-ovarian axis, 134–5, 157
- hypothyroidism, 243
- idiopathic epilepsy. *See* genetic generalized epilepsies (GGE)
- idiopathic generalized epilepsies, 124, 157, 178
- idiopathic generalized epilepsy (IGE). *See also* genetic generalized epilepsies (GGE)
- inactive epilepsy, 1
- Indigenous Australians, 129
- Indigenous girls and adolescent women, 129–30
- infants
- caring for, 185
 - exposed to in utero VPA monotherapy, 13
 - risks of major congenital malformations, 13
 - small for gestational age (SGA), 14, 233
 - unfavorable neurodevelopment in, 220
- infarction or intracerebral hemorrhage, 247
- infertility. *See also* fertility antiseizure medications (ASMs), 161–3
- counseling, evaluation and treatment, 163
 - definition of, 149
 - direct biological effects and, 156
 - epidemiology of, 150–4
 - etiology and characteristics of, 154–63
 - psychosocial issues and, 155
 - women with epilepsy and, 164
- injection
- depot, 143
 - intramuscular, 172

- injection (cont.)
 intravascular, 243, 259
 intravenous, 135
 insomnia, 51, 52, 53–4
 prevalence of in
 menopause, 59
 role of pharmacotherapy in
 treating, 54
 sleep maintenance, 6
 intelligence quotient (IQ)
 scores
 higher, 209
 lower, 14
 verbal, 181, 182
 VPA-exposed children, 206
 interictal discharges
 effects of seizures on, 48
 effects of sleep on, 48–9
 interictal dysphoric
 disorder, 28
 interictal psychosis, 30
 International Board-Certified
 Lactation Consultants
 (IBCLCs), 281
 International Classification of
 Sleep Disorders
 (ICSD-3), 52
 International Commission on
 Radiological
 Protection, 242
 International League Against
 Epilepsy guidelines, 223
 International League Against
 Epilepsy Task Force on
 Comorbidities, 123
 interpersonal therapy (IPT), 37
 intramuscular injection, 172
 intrapartum and postpartum
 management, 237–9
 intrauterine device (IUD), 170–2
 iodinated contrast medium,
 effect on the fetus, 243
 iodinated-based contrast
 medium, 253
 IQ scores
 difference for breastfed
 children, 17
 higher, 209
 lower, 14
 maternal, 180
 verbal, 181, 182
 VPA-exposed children
 and, 206
 juvenile absence epilepsy (JAE)
 sex differences and, 8
 juvenile myoclonic epilepsy
 (JME), 107, 115–16,
 124, 183
 Kerala Registry of Epilepsy and
 Pregnancy (India), 194,
 222, 224, 269
 ketamine, 261
 ketogenic diet, 289
 Kleine–Levin syndrome, 52
 labor and delivery
 management of seizures
 during, 225
 risk of seizures during,
 224, 237
 lacosamide (LCM), 88, 204,
 268, 285, 288
 clearance, 218
 younger patients and, 110
 lactation (breastfeeding),
 16–17, 18, 183
 antiseizure medications
 (ASMs) and, 284–7
 counseling and support for
 WWE, 289–90
 psychotropic medications
 in, 35–7
 rufinamide and, 289
 lamotrigine (LTG), 266–7, 285,
 294, 315
 lamotrigine clearance,
 217, 224
 malformations and use of,
 200–1
 left temporal lobe epilepsy
 PCOS and, 158
 left temporal lobe
 epilepsy (TLE)
 sexual dysfunction and, 9
 left temporal lobectomy
 (TLE), 111
 Lennox–Gastaut syndrome, 144
 and autism spectrum
 disorder, 32
 lesional epilepsy, 101
 levetiracetam, 285
 levetiracetam (LEV), 13, 87,
 220, 221, 267, 284,
 294, 315
 effectiveness of, 114
 risks of malformations
 and, 202
 libido, 155
 decreased, 27, 84, 87, 88, 125
 disorder of, 86
 lifestyle modifications, 40,
 271, 273
 light therapy, 40
 limbic system, the, 28
 Liverpool and Manchester
 neurodevelopmental
 group (LMNG)
 study, 206
 localized cortical electrical
 stimulation, 39
 Locock, Charles, 134
 loss of libido. *See* libido
 low-grade gliomas, 251
 luteinizing hormone (LH), 135
 magnetic resonance imaging
 (MRI), 241–2, 243–4
 contrast used with, 252
 major congenital malformations
 (MCMs), 13, 144, 169,
 220, 228
 folic acid and, 12
 risks of, 233, 279
 major depression, 4
 major depressive disorder
 (MDD), 26–7
 treatment of, 37–40
 major depressive episodes
 (MDEs), 26
 with onset during
 pregnancy, 27
 malformations
 antiseizure medications
 (ASMs) and, 279–80
 carbamazepine use and,
 198–200
 congenital, 193–4, 301
 during the first trimester, 206
 lamotrigine use and risks of,
 200–1
 major congenital, 220, 228
 of offspring of women with
 epilepsy and general
 population, 194
 phenobarbital risks and, 198
 risk of major congenital, 233
 risks from using antiseizure
 medications, 204
 risks from using topiramate
 and, 203
 risks of using levetiracetam
 (LEV) and, 202
 risks of using oxcarbazepine
 and, 203
 risks of using phenytoin
 and, 201–2

- risks of using zonisamide and, 203
- valproic acid use and, 201
- manic depression, 28–9
- marriage, 154, 161
 - arranged, 128
 - bans on, 149
 - lower marriage rates, 10
 - reduced rate for people with epilepsy, 128–9
 - social factors and, 154
 - women with epilepsy and, 3
- maternal epilepsy, 169, 194, 234, 301
 - statistics, 293
- Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study, 145, 232, 268
- MeCP2 deficiency, 107
- Medical Birth Registry of Norway, 14
- Medical Expenditure Panel Survey Household Component, 232
- medical genetics
 - consultation, 236
- medical history and presentation, 241
- medication adjustments, 223
 - postpartum period and, 266
- medications
 - antiseizure, 9
 - compliance with, 124
 - psychotropic, 34–5, 37–9
 - risks of seizures before and during pregnancy, 183–5
 - switching, 222–3
 - teratogenic effects of, 191
- medicines
 - complementary and alternative, 40
 - ways to remember, 271
- medroxyprogesterone acetate, 143
- melatonin agonists, 54
- meningioma, 250
- menopause, 17, 306
 - catamenial epilepsy and, 145
 - early, 307–8
 - hormonal changes in, 306–7
 - hormone replacement therapy (HRT) and sleep quality, 59
 - hypoestrogenism in, 17
 - insomnia and, 59
 - menopausal sleep complaints, 51
 - premature, 159
 - seizures and, 308
 - sleep and, 58
 - sleep-disordered breathing (SDB), 58
- menstrual cycle
 - catamenial epilepsy and, 65
 - epilepsy surgery and changes in, 161
 - hypothalamic-pituitary-ovarian axis and, 134–5
 - neuroactive sex hormones, 135
 - sleep and, 51
- menstrual disorders
 - risk of infertility due to, 9–11
 - statistics for women with epilepsy (WWE), 9
- menstrual irregularities, 84
- meperidine neurotoxicity, 262
- metabolite monohydroxy carbazepine (MHD), 286
- metastatic
 - choriocarcinoma, 251
- methylenetetrahydrofolate reductase (MTHFR), 208
- Metropolitan Atlanta Congenital Defects Program (MACDP), 202
- microsomal hepatic enzyme, 84
- mindfulness-based cognitive behavior therapy (MBCT), 37
- Minnesota, United States
 - age and gender-specific incidence of epilepsy in, 3
- monoamine oxidases (MAOs), 26
- monotherapy, 180, 234, 301
 - exercise, 40
 - in pregnancy, 208
 - vs. polytherapy, 181, 204–5
- mood disorders, 4–5, 265
- mood monitoring, 273–4
- multiple sleep latency test (MSLT), 52
- multisystem disorder, 244
- National Medical Birth Registry, Finland's, 13
- NEAD study, 181, 183, 206, 207, 297, 300
 - preconception folic acid supplementation, 181
 - valproate and ADHD, 208
 - women on ASMs
 - monotherapy in the, 206
- neural tube defect (NTD), 236
 - assessing for, 236
 - folic acid and, 222
- neuroactive sex hormones, 135, 138
- neurocognitive development, 207, 300
- neurocognitive problems, 31–2
- neurodevelopment, 223, 300–1
 - unfavorable
 - neurodevelopmental in infants, 220
- neurodevelopmental disorders, 114
 - evaluation of, 123
 - global neurodevelopment and adaptive behavior, 207
 - MECP2* duplication in males and, 109
- Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study, 180, 206, 281
- neuroexcitatory role via inhibition of GABA, 50
- neuroimaging, 244, 245
 - in non-pregnancy-related conditions, 251–2
 - in pregnancy, 241–2, 253
 - pregnant women and, 252–3
- neurologic disorder, in pregnancy, 293
- neuromodulators, 77
- neuromuscular blocking agents, 261–2
- neuronal migration and organization, 300
- neuronal tube defect (NTD), 200
- NeuroPace trial, 48
- neuropsychiatric disorders, 25, 293
 - risks for women on medications for, 297
- neurosteroids as anticonvulsant agents
 - clinical trials, 74–7

- neurostimulation, 39
 newborn. *See also* fetus
 care of the, 274, 294
 feedings and care of during
 the postpartum
 period, 276
 gadolinium-based contrast
 medium and safety
 of, 244
 physical examination of the,
 297–8
 new-onset seizures in
 pregnancy, 226
 N-methyl D-aspartate
 (NMDA) receptor
 complex, 307
 nocturnal behaviors, 52
 non-benzodiazepine
 hypnotics, 54
 non-catamenial epilepsy, 216,
 See also catamenial
 epilepsy
 non-enzyme-inducing
 antiseizure medications
 (ASMs), 18, 84, 85,
 86–8, *See also* enzyme-
 inducing antiseizure
 medications (ASMs)
 transwomen use and, 130
 nonhormonal strategies
 management of catamenial
 epilepsy with,
 144–5
 normeperidine, 262
 North American AED
 Pregnancy Registry
 (NAAPR), 13, 194
 North American Antiepileptic
 Drug Pregnancy
 Registry data, 233
 North American ASM
 Pregnancy Registry, 181
 North American Commission
 of the International
 League Against
 Epilepsy, 129
 Norwegian Medical Birth
 Registries (MBRN), 194
 Norwegian Mother and Child
 Cohort Study
 (MoBa), 281
 obstetric anesthesia, 257
 airway management, 257–8
 obstructive sleep apnea (OSA),
 6, 51
 offspring affected with
 epilepsy, 7
 oligomenorrhea, 86, 161
 hyperprolactinemia and, 159
 omega-3 fatty acids, 40
 opioid analgesics, 262
 oral contraceptives, 170, 172–3
 management of catamenial
 epilepsy, 143
 oral contraceptive pills
 (OCPs), 41
 osteopenia, 89, 90, 314
 pharmacologic therapy
 and, 314
 osteoporosis, 17–18, 41, 90,
 310–11
 family history of, 313
 of hip and lumbar spine, 89
 pharmacologic therapy
 and, 314
 vitamin D and, 314
 ovulation-sparing, 306
 oxcarbazepine (OXC), 13, 15,
 86, 93, 110, 163, 176,
 220, 221, 267, 286, 294,
 315, *See also*
 pharmacokinetics
 risks of malformations from
 use of, 203
 Patient Health Questionnaire-9
 (PHQ-9), 32
 PCDH 19 epilepsy, 113–14
 perampanel, 90, 204, 218, 288
 perimenopausal insomnia, 59
 perimenopause
 hormone levels and, 65
 perimenopausal
 depression, 27
 perimenopausal women and
 bone health, 309–10
 seizures and, 308
 treatment of perimenopausal
 depression, 40
 perinatal depression, 27
 treatment of, 40
 periodic limb movement
 disorder, 55
 periodic limb movements
 in sleep in pregnancy, 58
 peripartum depression, 273
 periventricular nodular
 heterotopia, 107,
 112–13
 pharmacokinetic changes
 in pregnancy, 223
 pharmacokinetics, 174, 202
 effect on the efficiency of
 ASMs, 217
 of antiseizure medications
 (ASMs), 215
 pharmacotherapy, 37, 40
 role of, 54
 phenobarbital (PB), 13, 85, 198,
 268, 287, 315
 concentrations of, 138
 phenytoin (PHT), 13, 85, 268,
 287, 315
 malformations and use of,
 201–2
 PMDD. *See* premenstrual
 dysphoric disorder
 (PMDD)
 polycystic ovary syndrome
 (PCOS), 9, 86, 158
 polymenorrhea,
 hyperprolactinemia
 and, 159
 polysomnography (PSG), 47,
 50, 61
 polytherapy, 216, 234, 300
 vs. monotherapy, 181,
 204–5
 Posterior Reversible
 Encephalopathy
 Syndrome (PRES),
 245
 postictal somnolence, 48
 postmenopausal women, 54,
 58, 309
 on antiseizure medications
 (ASMs), 311
 phenytoin use and, 315
 treated with raloxifene, 314
 postnatal development
 development and
 growth, 300
 long-term follow-up, 300
 postnatal management,
 299–300
 physical examination, 300
 postpartum care plan, 265,
 269–71, 270
 postpartum cerebral
 angiopathy, 249–50
 postpartum depression, 4, 27,
 185, 289
 anxiety and, 281
 breastfeeding risk and,
 274–6
 risk factors for, 273
 statistics about, 235

- postpartum period, 265, 276
 breastfeeding and epilepsy during the, 274–6
 counseling about
 postpartum safety, 269
 developing safety plans for women and babies, 276
 home safety strategies, 275
 medication adjustments during, 266
 mood monitoring during, 273–4
 newborn care during, 274
 newborn feedings and care during the, 276
 postpartum management, 237–9
 self-management during, 271
 postpartum psychosis, 31, *See also* postpartum depression
 preconception counseling, 11–12, 168–9, 177, 185, 221, 228, 236, *See also* counseling
 elements of, 178
 preconception planning, 125, 130, 177, 182, 185, 221, *See also* preconception counseling
 preconception seizures, 216
 preconceptual folic acid, use of, 11
 predischARGE assessment, 299–300
 preeclampsia, 16
 and eclampsia, 244–7
 and eclampsia as risk factors for cerebral venous thrombosis, 247
 and eclampsia diagnosis, 258
 preterm births and, 294
 severe, 16
 pregabalin, 85
 treatment for restless leg syndrome, 55
 pregabalin (GABA analog ASMs), 87
 pregnancy
 catamenial epilepsy and, 145
 comorbid conditions in, 244
 complications and epilepsy, 15–16
 doses of antiseizure medication (ASMs), 266
 effects of epilepsy on, 231–3
 hypertensive disorders of, 235
 monitoring, 238
 neuroimaging in, 241–2, 252–3, 253
 new-onset epilepsy during, 293
 ongoing care, 237
 pharmacokinetic changes in, 223
 pregnancy-related sleep disorders, 57
 psychotropic medications in, 35–7
 restless legs syndrome in sleep in, 58
 risk of antiepileptic drugs in, 178–82
 risk of seizures during, 182–3
 risks of medications and seizures during and after, 183–5
 risks related to seizures during, 182
 safety and social support, 185
 safety of the fetus, 242–4
 seizure control during, 15, 228
 seizure deterioration in, 215
 seizure frequency during, 182
 seizures during, 215–16
 sleep and, 56–7
 sleep-disordered breathing in, 57
 teratogenesis in repeated pregnancies, 205–6
 therapeutic drug monitoring (TDM) during, 223
 women with epilepsy and, 61
 Pregnancy and Lactation Labeling Rule (PLLR), 192
 pregnancy registries, 194–8
 characteristics of, 196–7
 pregnant Meyer's serum gonadotropin (PMSG), 67
 premature menopause, 159
 premenstrual dysphoric disorder (PMDD), 27–8
 treatment of, 40–1
 premenstrual syndrome (PMS), 27
 Prempro, controlled trial of, 308
 preterm births, 294
 primidone, 287
 proconvulsants, progesterone as, 71–2
 progesterone, 51, 64–5, 135, 137
 anticonvulsant and seizure-promoting effect of, 68
 anticonvulsant effects, 70–1
 proconvulsant effects, 71–2
 progesterone therapies for catamenial epilepsy, 142–4
 propofol, 261
 pseudopregnancy model, 66
 psychiatric comorbidities
 epilepsy and, 122
 in childhood, 122–3
 psychiatric disorders, 4–6, 113, 194
 as a comorbidity in children with epilepsy, 122
 biological antagonism between neurological and, 39
 comorbid, 25
 neuropsychiatric disorders, 25, 297
 psychiatric phenomena, and epilepsy, 25
 psychiatry, 4–6
 psychogenic non-epileptic seizures (PNES), 33–4
 impact on quality of life, 34
 treatment of, 42
 psychomotor retardation, 37
 psychosis, 29–31
 interictal, 30
 postpartum, 31
 treatment of, 41
 psychotherapy, 37
 psychotropic medications, 36, 37–9
 risk of seizures from using, 34–5
 use in pregnancy and breastfeeding 47, 35–7
 puerperium, 267
 cerebral venous thrombosis in, 247, 248
 valproic acid (VPA) monitoring and, 268
 quality of life
 comorbid psychiatric disorders, 25
 effect of aging on, 316

- quality of life (cont.)
 effect of comorbid mental health disease on, 316
 effect of epilepsy on, 146
 effect of major congenital malformation (MCM) on, 193
 effect of stimagitzation on, 126
 for adolescents with epilepsy, 124, 125
 impact of ADHD on for children, 123
 improvement in with HRT, 59
 loss of driver's license and, 221
 of persons with epilepsy, 88
 psychogenic non-epileptic seizures (PNES) and, 34
 reduction in for people with epilepsy, 9, 46, 52
 restless legs syndrome and reduction in, 55
 Rett syndrome and, 108
 sleep disorders and, 6, 52, 53, 57, 61
- raloxifene, 314
 rape, rates of, 126
 repetitive transcranial magnetic stimulation (rTMS), 39
 reproductive disorders, 158
 hyperprolactinemia, 159
 hypothalamic hypogonadism, 158–9
 polycystic ovary syndrome (PCOS), 158
 premature menopause, 159
 sex hormones alterations, 159
 reproductive disturbances. *See also* reproductive disorders
 antiseizure medications (ASMs) and, 161–3
 chronic epilepsy and acute seizures, 160
 epilepsy surgery and, 161
 in women with epilepsy (WWE), 160
 laterality of the epileptic lesion, 160–1
 reproductive dysfunction and fertility, 9–11
 reproductive hormones
 effects of antiepileptic drugs on, 174–6
 female, 64–5, 77
 reproductive rights, 149
 Presidential Task Force on Redefining the Postpartum Visit of the American College of Obstetricians and Gynecologists, 269
 restless legs syndrome, 55
 in sleep in pregnancy, 58
 Rett syndrome (RTT), 107–9
 right temporal lobe epilepsy, 139
 sexual dysfunction and, 9
 Rochester study, 155
 rufinamide, 218, 289
- S-adenosylmethionine (SAM-e), 40
 schizoaffective disorders, 293
 seizure control, 46, 124, 145, 182, 186, 194, 271, 279
 and development of psychosis, 30
 catamenial epilepsy, 216
 continuous positive airway pressure (CPAP) and, 55
 contraceptives for, 176–7
 DMPA effects on, 176
 during pregnancy, 15
 during pregnancy and pharmacokinetics, 217
 hormonal contraceptives and, 176
 impact of, 29
 improved sleep and, 48
 inadequate, 299
 incomplete, 161
 lamotrigine for better, 87
 lifestyle modifications, 273
 medroxyprogesterone acetate (MPA) for, 143
 poor, 52
 preconception and, 216, 222, 223
 pregnancy and, 145, 183, 215, 216, 222, 228, 231, 237, 266
 seizure exacerbation, 11, 53, 65–6, 77, 123, 144, 146, 164
 ADHD fears and, 123
 catamenial, 77, 134, 138, 143
 cyclic, 308
 cyclical, 135
 during ovulatory, 65
 patterns of, 139
 perimenstrual, 71, 138
 seizure triggers, adolescents, 124
 seizure/seizures
 action plan, 272, 272–3
 acute symptomatic, 101
 bilateral tonic-clonic, 8, 135
 breakthrough, 274
 consequences of during pregnancy, 218–21
 deterioration in pregnancy, 215
 during labor and delivery, 224
 effects of chronic, 160
 effects of on sleep, 48–9
 from eclampsia versus epilepsy, 225
 generalized tonic-clonic, 48, 115
 in non-pregnancy related conditions, 251–2
 menopause and perimenopause and, 308
 monitoring and tracking of, 271–2
 preconception, 216
 psychotropic medications risks, 34–5
 refractory, 144
 risk of during pregnancy, 182–3
 risks for, 301
 secondary to eclampsia, 225
 secondary to epilepsy, 224–5
 single, 1
 tonic-clonic, 72, 182
 trigger minimization and lifestyle modifications, 273
 types of, 108
 unprovoked incidence of, 101
 water balance and, 137
 selective amygdala hippocampectomy, 161
 selective estrogen receptor modulators (SERM), 314
 selective serotonin reuptake inhibitors (SSRIs), 37
 self-image, adolescents and, 124–5

- Selye, Hans, 64
- serotonin-norepinephrine reuptake inhibitors (SNRIs), 37
- sevoflurane, 261
- sex and gender differences
2SLGBTQIA+ populations and, 130
- in epilepsies, 8
- sex hormones, 156
- neuroactive, 135
- sex hormones alterations, 159
- sex-hormone-binding globulin (SHBG)
concentrations, 85
- sexual awakening, in
adolescence, 124–5
- sexual desire, 87
- and mood, 155–6
- decreased, 9
- sexual dysfunction, 8–9, 88
- gender differences and, 125
- in women with epilepsy (WWE), 156
- menopause and, 17
- mood and, 155–6
- postoperative improvement of, 161
- European database statistics on, 86
- sex hormones level and, 156
- temporal lobe epilepsy (TLE) and, 156
- sexually transmitted infection (STI) prevention, 173
- single seizures, 1
- sleep
- effect of antiseizure medications (ASMs) on, 50
- epilepsy and, 47–8
- excessive daytime sleepiness, 52
- good rules for, 53
- hormonal influences on, 50–1
- hormone replacement therapy (HRT) and quality of, 59
- menopause and, 58
- menstrual cycle and, 51
- non-REM (NREM), 47
- physiology of, 46–7
- rapid eye movement (REM), 47
- restless legs syndrome and periodic limb movement in pregnancy, 58
- sleep comorbidities, 52
- excessive daytime sleepiness, 52
- insomnia, 53–4
- restless legs syndrome, 55
- sleep-disordered breathing, 54–5
- sleep deprivation, 124, 224
- postpartum period and, 289
- sleep disorders
- epilepsy and, 46
- in pregnancy, 57
- in women with epilepsy, 61
- medicine consultation and polysomnography for, 61
- sleep-related respiratory events, 57
- sleep disruption, 6–7, 287
- causes of, 51, 56
- cognitive impairments and, 61
- comorbid, 52
- method of feeding an infant and, 57
- restless leg syndrome and PLMS and, 58
- sleep disturbances. *See* sleep disruption
- Sleep Heart Health study, 59
- sleep-disordered breathing (SDB), 51, 52, 53, 54–5, 56, 61
- diagnosis of, 52
- hormone replacement therapy and, 59
- in menopause, 58
- in pregnancy, 57
- treating, 56
- sleep-related hypermotor epilepsy (SHE), 47
- small for gestational age (SGA) infants, 14, 233
- social anxiety disorder (SAD), 41
- Social Emotional Questionnaire, 208
- specific absorption rate (SAR), 243
- spontaneous abortion, 203, 228, 233, 234
- folic acid supplementation and, 12, 181
- monotherapies and, 233
- risk of, 154
- St. John's wort, 40
- status epilepticus, 66, 71, 73–4, 228, 237
- controlling, 260
- controlling refractory, 261
- during delivery, 224
- ECT can be used in refractory, 39
- electrical status epilepticus during sleep (ESES), 108
- inhibitory mechanisms, 49
- lidocaine and, 260
- nonconvulsive or convulsive, 113
- normal treatment of, 225
- pregnancy-associated, 228
- synthetic neurosteroid brexanolone as treatment for super-refractory, 74
- stigma/stigmatization, 126
- effect on fertility, 154–5
- Study of Osteoporotic Fractures, 312
- subclinical hypothyroidism, risk factors for, 92
- subcortical band heterotopia, 107, 110–12
- sudden infant death syndrome (SIDS), 274
- sudden unexpected death in epilepsy (SUDEP), 48, 182, 220, 235
- sugammadex, 262
- suicidal ideation, 32–3
- suprachiasmatic nucleus (SCN), 51
- Swedish National Registry, 194
- Swiss study
- statistics of sleep disturbances in adults with epilepsy patient, 6
- synthetic neurosteroid brexanolone, 74
- temporal and frontal seizure foci, 28
- temporal lobe epilepsy (TLE), 9, 29, 31, 65, 139, 156, 159, 160–1
- amenorrhea and, 158

- temporal lobe epilepsy (cont.)
 catamenial epilepsy pattern
 and, 139
 HPG function in men
 with, 160
 on polytherapy, 218
 PCOS and, 160
 progesterone receptors,
 72
 reproductive disorders
 in, 159
 status epilepticus and, 66
 temporal lobectomy, 161
 teratogenesis, 191–2
 principles of, 192–3
 repeated pregnancies and,
 205–6
 teratogenicity, 232, 236
 antiseizure medications
 (ASMs) and, 194, 221
 neurodevelopmental, 169
 of antiseizure medications
 (ASMs), 128
 risk of, 222, 237
 risks for, 183
 testosterone, 51
 therapeutic drug monitoring
 (TDM), during
 pregnancy, 223
 thrombotic thrombocytopenic
 purpura (TTP), 247
 thyroid
 prevalence of thyroid
 dysfunction, 92
 subclinical hypothyroidism
 risks, 92
 thyroid hormones and
 antiseizure medications
 (ASMs), 92–3
 tonic-clonic seizures, 72, 109,
 182, 234, 262
 bilateral, 8, 135
 generalized, 48, 115, 159,
 220, 222, 225, 260, 313
 in pregnancy, 220
 monotherapy for, 15
 topiramate (TPM), 13, 34, 86,
 92, 267, 286, 316
 risks of malformations from
 using, 203
 total energy deposited
 (dose), 242
 transdermal patch, 173
 transwomen, 130
 traumatic brain injury, 2, 101
 treatment options
 evidence-based, 134
 for catamenial epilepsy, 139
 for infertility, 163
 psychotropic medications
 as, 35
 UK Pregnancy Registry
 (UKEPR), 194, 200, 207
 limitation of, 195
 risk of major congenital
 malformations and
 ASM polytherapy, 205
 risk of major congenital
 malformations with
 zonisamide, 203
 statistics, 201
 topiramate monotherapy
 exposure, 203
 United Kingdom, maternal
 death and epilepsy,
 235
 unborn child, safety of, 242–4
 unintended pregnancies
 in the United States, 11
 United Nations, breastfeeding
 advocacy and, 280
 US Food and Drug
 Administration
 (FDA), 32
 unplanned pregnancies, 11,
 169, 170
 general population for
 women with epilepsy
 (WWE), 11
 unprovoked seizures, incidence
 of, 101
 upper airway resistance
 syndrome, 57
 uridine diphosphate
 glucuronosyl
 transferases (UGT), 92,
 266, 283
 United States, maternal death
 and epilepsy, 235
 vaginal ring, 173, 175
 valproate (VPA), 10, 86, 91,
 158, 162, 176, 316
 for bipolar disorders, 34
 valproic acid (VPA), 13, 85,
 218, 268, 286–7, 294
 malformation risk from use
 of, 201
 withdrawal of use during
 pregnancy, 223
 verbal intelligence scores, 207
 vitamin D metabolism/
 supplementation, 89,
 90, 306, 310, 312, 314
 accelerated, 311
 volatile anesthetics, 261
 water balance, seizures
 and, 137
 weight, antiseizure
 medications (ASMs)
 and, 90–2
 West syndrome and autism
 spectrum disorders, 32
 Women's Health Initiative
 trial, 59
 World Health Organization
 (WHO), 194
 breastfeeding advocacy
 and, 280
 fracture risk assessment
 tool, 313
 X-linked epilepsies, 113
 zolpidem, 54, 57
 zonisamide (ZNS), 88, 92, 218,
 267, 286, 294, 316
 effects of on sexual
 function, 88
 risks of malformations
 and, 203
 weight issues and use of, 92